ADCT Stock Overview
Focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ADC Therapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.39 |
| 52 Week High | US$6.04 |
| 52 Week Low | US$0.68 |
| Beta | 1.6 |
| 11 Month Change | -23.40% |
| 3 Month Change | -18.43% |
| 1 Year Change | 239.68% |
| 33 Year Change | -89.54% |
| 5 Year Change | n/a |
| Change since IPO | -91.94% |
Recent News & Updates
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Nov 16
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Recent updates
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Nov 16ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09Shareholder Returns
| ADCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | -10.9% | -2.2% |
| 1Y | 239.7% | 13.9% | 30.1% |
Return vs Industry: ADCT exceeded the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: ADCT exceeded the US Market which returned 30.1% over the past year.
Price Volatility
| ADCT volatility | |
|---|---|
| ADCT Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADCT's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 274 | Ameet Mallik | www.adctherapeutics.com |
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
ADC Therapeutics SA Fundamentals Summary
| ADCT fundamental statistics | |
|---|---|
| Market cap | US$231.09m |
| Earnings (TTM) | -US$212.15m |
| Revenue (TTM) | US$70.72m |
3.3x
P/S Ratio-1.1x
P/E RatioIs ADCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADCT income statement (TTM) | |
|---|---|
| Revenue | US$70.72m |
| Cost of Revenue | US$130.57m |
| Gross Profit | -US$59.85m |
| Other Expenses | US$152.30m |
| Earnings | -US$212.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | -84.64% |
| Net Profit Margin | -300.00% |
| Debt/Equity Ratio | -258.2% |
How did ADCT perform over the long term?
See historical performance and comparison